• Careers
  • News
  • Publications
  • Contact Us
  • Company
    • About Us
    • Management Team
    • Board of Directors
    • Collaborations
    • Careers
    • Contact Us
  • Therapeutic Areas
    • Oncology
    • Publications
  • Programs
    • Pipeline
    • mTORC1/2 inhibitor Sapanisertib
    • SYK Inhibitor Mivavotinib
    • Preclinical Programs
  • Clinical Trials
    • Clinical Trials Overview
    • Expanded Access
  • Investors
    • Corporate Profile
    • Press Releases
    • Event & Presentations
    • Stock Information
    • Financial Information
      • Overview
      • SEC Filings
      • Ownership Summary
    • Analyst Coverage
    • Corporate Governance
      • Highlights
      • Board of Directors
      • Management Team
      • Committee Composition
    • Shareholder Services
      • Investor FAQs
      • E-mail Alerts
    • Proxy & Annual Report
    • Contact Us
  • Careers
  • News
  • Publications
  • Contact Us

CB-668 IL4I1 Inhibitor

Post navigation

Previous PostPrevious
Next PostNext
Company
  • About Us
  • Management Team
  • Board of Directors
  • Collaborations
  • Careers
  • Contact Us
Therapeutic Areas
  • Oncology
  • Publications
Programs
  • Pipeline
  • mTORC1/2 inhibitor Sapanisertib
  • SYK Inhibitor Mivavotinib
  • Preclinical Programs
Clinical Trials
  • Clinical Trial Overview
  • Expanded Access
Investors
  • Corporate Profile
  • Press Release
  • Events & Presentations
  • Stock Information
  • Financial Information
  • Analyst Coverage
  • Corporate Governance
  • Shareholder Services
  • Proxy & Annual Report
  • Contact Us
© 2022 Calithera Biosciences, Inc. All rights reserved.
ETHICS & COMPLIANCEPRIVACY POLICYLEGAL TERMS OF USE
  • Contact Us
  • News
CALITHERA® and the Calithera logos are trademarks or registered trademarks of Calithera Biosciences, Inc.
CALITHERA® and the Calithera logos are trademarks or registered trademarks of Calithera Biosciences, Inc.